Plavix, Clopidogrel Wire
Comprehensive News Feed for Plavix, Clopidogrel (generic).
Results 1 - 20 of 2,538 in Plavix, Clopidogrel (generic)
-
Certain reflux drugs tied to higher post-angioplasty death rate
People taking the acid reflux drugs Prilosec or Protonix in combination with blood thinners such as Plavix have a higher risk for death after angioplasty than people who don't take the two popular antacids, a new study has found. Comment?
-
Jurriën ten Berg, interventional radiologist at St. Antonius Hospital, Nieuwegein, Netherlands Late-breaking clinical trial news CHAMPION fails to top podium as antiplatelet star Two large companion trials have failed to show the superiority of the new reversible antiplatelet drug cangrelor compared to standard therapy using clopidogrel. Comment?
-
Image of the Month--Quiz Case [Special Feature]
Image of the Month - Quiz Case Dinesh N. Ratnapala, MB, ChB ; David Lisle, FRACR ; Elizabeth Munn, FRCPA ; Andreas L. Lambrianides, FRACS Arch Surg. Comment?
-
Aspirin Without Plavix as Good After Heart Bypass
Aspirin alone proved as effective as aspirin plus the blood clot preventer Plavix in keeping coronary artery bypass grafts open during the first year after surgery, according to a study released on Monday. Comment?
-
Certain Reflux Drugs Tied to Higher Post-Angioplasty Death Rate
People taking the acid reflux drugs Prilosec or Protonix in combination with blood thinners such as Plavix have a higher risk for death after angioplasty than people who don't take the two popular antacids, a new study has found. Comment?
-
New Anti-Clotting Medication Not More Effective than Standard Care
" Two large studies confirmed that an investigational, reversible anti-clotting medication failed to show greater effectiveness than clopidogrel or a placebo for patients undergoing a procedure to open blocked coronary arteries, according to researchers at the Duke Clinical Research Institute. Comment?
-
Merck Announces Completion of Patient Enrollment in Phase III...
More than 26,000 Patients Enrolled in Global Trial Evaluating Investigational Antiplatelet Agent in the Long-Term Prevention of Cardiovascular Events Whitehouse Station, NJ, Nov. Comment?
-
Popular Anti-Platelet Therapy Reduces Risk of Cardiovascular Events in Men and Women, Study
Popular Anti-Platelet Therapy Reduces Risk of Cardiovascular Events in Men and Women, Journal of the American College of Cardiology Study 11/16/2009 ScienceDaily a ' A new study, published in the November 17, 2009, issue of the Journal of the American College of Cardiology, adds to a growing body of research seeking to evaluate and understand ... Comment?
-
Patients Suffering STEMI Fare Better with Ticagrelor Therapy, Study
The investigational platelet aggregation inhibitor ticagrelor appeared to produce better outcomes in patients with high-risk, acute coronary syndromes than clopidogrel (Plavix), investigators reported here in a finding that mirrored results of an earlier, larger study. Read at MedPageToday Comment?
-
The Medicines Company's Full Analysis Of CHAMPION Phase III Data...
Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials ; Heart Disease Article Date: 16 Nov 2009 - 3:00 PST The Medicines Company announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. Comment?
-
AstraZeneca Drug Tops Plavix in Sickest Patients
Heart attack patients in need of emergency procedures were less likely to suffer further serious cardiovascular events, including death, when given AstraZeneca's experimental Brilinta blood clot preventer than those who used Plavix, according to a study presented on Sunday. Comment?
-
Will Plavix Competitor Cangrelor Be a Prince Rather than a Frog for The Medicines Co.?
w/Photo
The Medicines Co. , which six months ago stopped two likely-to-fail Phase III trials of antiplatelet drug cangrelor , is out to prove its frog of a drug may be a prince after all. Comment?
-
AstraZeneca Drug Beats Plavix for Myocardial Infarction
An experimental anti-clotting drug being developed by AstraZeneca was shown to be more effective than PlavixA in treating heart patients who have the most serious type of acute coronary syndrome, those with ST segment elevation myocardial infarction . Comment?
-
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose...
Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease and received a 60 mg loading dose and 10 mg maintenance dose of Effient achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix . Comment?
-
New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
This was associated with reduced cardiovascular and all cause mortality. -No increase in major bleeding incidents was reported. Comment?
-
Video: Ticagrelor (BRILINTA(TM)) Demonstrated Greater Efficacy Over...
AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome patients, those with ST Segment Elevation Myocardial Infarction . Comment?
-
American Heart Association Late Breaking Clinical Trial Report: Tests ...
Study highlights: -- Three of six platelet reactivity tests predicted a risk of adverse outcomes related to blood clots in patients receiving two anti-clotting drugs following angioplasty plus stenting. Comment?
-
Intravenous Platelet Blockade with Cangrelor during PCI
Deepak L. Bhatt, M.D., M.P.H., A. Michael Lincoff, M.D., C. Michael Gibson, M.D., Gregg W. Stone, M.D., Steven McNulty, M.S., Gilles Montalescot, M.D., Ph.D., Neal S. Kleiman, M.D., Shaun G. Goodman, M.D., Harvey D. White, D.Sc., Kenneth W. Mahaffey, M.D., Charles V. Pollack, Jr., M.D., Steven V. Manoukian, M.D., Petr Widimsky, M.D., Dr.Sc., Derek ... Comment?
-
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
Robert A. Harrington, M.D., Gregg W. Stone, M.D., Steven McNulty, M.S., Harvey D. White, D.Sc., A. Michael Lincoff, M.D., C. Michael Gibson, M.D., Charles V. Pollack, Jr., M.D., Gilles Montalescot, M.D., Ph.D., Kenneth W. Mahaffey, M.D., Neal S. Kleiman, M.D., Shaun G. Goodman, M.D., Maged Amine, M.D., Dominick J. Angiolillo, M.D., Ph.D., Richard ... Comment?
-
Cangrelor a " A Champion Lost in Translation?
Published at www.nejm.org November 15, 2009 Adnan Kastrati, M.D., and Gjin Ndrepepa, M.D. Current guidelines recommend the early use of drugs that block platelet adenosine diphosphate receptor P2Y12 in patients with acute coronary syndromes in whom percutaneous coronary intervention may be performed. Comment?
Plavix, Clopidogrel Forum
Most Popular
- Arkansas 10-Year-Old Won't Pledge Allegiance Until Gays Gain Equality. - 1,015 comments
- Obama's Muslim Problem - Has he been too conciliatory? - 231 comments
- Napolitano pronounces US border more secure now - 154 comments
- Churches targeted by 'gay' intimidation campaign - 224 comments
- Obama urges Congress to put off Fort Hood probe - 125 comments
- 'You lie!' poll: Half of Southern Democrats upset - 74 comments
- Immigrant Bill Is Back on Table - 91 comments
- France accuses Israel of not wanting peace - 89 comments
- Five arrests in Glasgow 'anti-Islam' protest - 77 comments
- Arrest at Walmart leads to charges of racism - 53 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
